Skip to main content.

Lisa A. Clough, MD

Lisa Clough portrait
Associate Professor, Infectious Diseases

Professional Background

Dr. Lisa Clough is an Associate Professor of Medicine at the University of Kansas Medical Center. She currently serves as Program Director of the Infectious Diseases Fellowship program and has been the division lead for Infectious Diseases Clinical Trials research for more than 15 years.
Dr. Clough received her medical degree from the University of Kansas Medical Center where she went on to complete her Internal Medicine Residency before serving as Chief Resistant for the program. She completed her Infectious Diseases Fellowship training at Vanderbilt University where she went on to begin her career in HIV-related patient care and research prior to re-locating to the Kansas City area.
As a member of the Clinical Infectious Diseases Faculty, Dr. Clough provides inpatient consultative care for patients with complex infectious disease problems. She serves on the Antibiotic Stewardship and Pharmacy and Therapeutics committees. In her outpatient clinic Dr. Clough has developed a focus on the care of persons living with HIV/AIDS. She created a collaborative HIV practice with the Department of Pharmacy Services to streamline convenience and safety of anti-retroviral prescribing, advance the field of HIV-related pharmaceutic research and provide pre-exposure prophylaxis care for patients interested in a specialist-led multidisciplinary clinic..
Dr. Clough is passionate about educating the Infectious Diseases physicians of the future. As the current Infectious Diseases Fellowship Program Director, she oversees the clinical, educational, scholarship and administrative initiates of this program. She is a member of the GME program director committee and the School of Medicine Executive committee. She also participates in the education of medical students and residents through didactic and bedside teaching. She is committed to creating a safe and welcoming learning environment and providing tools necessary to help learners develop into independent, inquisitive, and compassionate physicians who can thrive in roles of educators, scientists, and public health advocates.
Through her over 25 years in clinical research, Dr. Clough has been involved in the design and implementation of clinical research studies in many areas of Infectious Diseases. Her research and clinical trials experiences include work in bacterial, viral, and fungal therapeutics and infection prevention initiatives with a particular focus in infections in persons living with HIV and other immunocompromised hosts.

Education and Training
  • MD, Doctorate of Medicine, Univ. of Kansas-Medical Center
  • Residency, University of Kansas, Kansas city, Kansas
  • Clinical Fellowship, Infectious Diseases, Vanderbilt Univeristy, Nashville, Tn
Licensure, Accreditations & Certifications
  • Infecious Diseases Board Certification, Americal Board of Internal Medicine
  • Kansas Medical License, Kansas Board of Healing Arts



Dr. Clough has been involved in the design and implementation of clinical research studies in the field of Infectious Diseases for over 25 years. She has an extensive background in conducting clinical trials related to antimicrobial therapeutics in both early and late phase studies. Her research and clinical trials experiences include the study and management of complex bacterial, viral, and fungal infections with a specific interest in HIV, C. difficile and infections in immunocompromised hosts and transplant recipients.
Through her research work, Dr. Clough has had the opportunity to mentor countless learners in the field of Infectious Diseases research and strives to promote scholarship that inspires advancement and dissemination of new discoveries in the discipline

Current Research and Grants
  • A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallelgroup, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alfenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed, ViiV healthcare, PI